Early Treatment with Tecovirimat Against Mpox Disease in Cynomolgus Macaques

However, recent randomized clinical trials in patients with mpox who initiated tecovirimat an average of 6-9 days after onset of symptoms did not show improvement in time to resolution of skin lesions.

Here, we evaluated whether timing of tecovirimat initiation influenced antiviral efficacy following mpox infection in nonhuman primates and defined the therapeutic window for treatment initiation. Tecovirimat efficacy was strongly associated with timing of initiation of therapy. Treatment initiation on Day 2 largely prevented progressive skin lesions and plasma viral loads.